ARROWHEAD PHARMACEUTICALS, INC.: cash including restricted cash

What this measure means

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Exact concept: us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-09-30 to 2025-09-30. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• ARROWHEAD PHARMACEUTICALS, INC.: total assets
• ARROWHEAD PHARMACEUTICALS, INC.: stockholders equity
• ARROWHEAD PHARMACEUTICALS, INC.: cash and cash equivalents
• ARROWHEAD PHARMACEUTICALS, INC.: net income or loss
• ARROWHEAD PHARMACEUTICALS, INC.: operating cash flow
• ARROWHEAD PHARMACEUTICALS, INC.: capital expenditure payments
• ARROWHEAD PHARMACEUTICALS, INC.: revenue
• ARROWHEAD PHARMACEUTICALS, INC.: contract revenue excluding tax
• ARROWHEAD PHARMACEUTICALS, INC.: financing cash flow
• ARROWHEAD PHARMACEUTICALS, INC.: investing cash flow
• ARROWHEAD PHARMACEUTICALS, INC.: retained earnings or deficit
• ARROWHEAD PHARMACEUTICALS, INC.: basic weighted-average shares
• ARROWHEAD PHARMACEUTICALS, INC.: diluted weighted-average shares
• ARROWHEAD PHARMACEUTICALS, INC.: basic earnings per share
• ARROWHEAD PHARMACEUTICALS, INC.: diluted earnings per share
• ARROWHEAD PHARMACEUTICALS, INC.: income tax expense or benefit
• ARROWHEAD PHARMACEUTICALS, INC.: net property, plant and equipment
• ARROWHEAD PHARMACEUTICALS, INC.: share-based compensation expense
• ARROWHEAD PHARMACEUTICALS, INC.: operating income or loss
• ARROWHEAD PHARMACEUTICALS, INC.: current assets
• ARROWHEAD PHARMACEUTICALS, INC.: interest expense
• ARROWHEAD PHARMACEUTICALS, INC.: current liabilities
• ARROWHEAD PHARMACEUTICALS, INC.: current accounts payable
• ARROWHEAD PHARMACEUTICALS, INC.: net finite-lived intangible assets
• ARROWHEAD PHARMACEUTICALS, INC.: net current accounts receivable
• ARROWHEAD PHARMACEUTICALS, INC.: operating expenses
• ARROWHEAD PHARMACEUTICALS, INC.: research and development expense
• ARROWHEAD PHARMACEUTICALS, INC.: common shares outstanding
• ARROWHEAD PHARMACEUTICALS, INC.: additional paid-in capital
• ARROWHEAD PHARMACEUTICALS, INC.: accumulated other comprehensive income or loss
• ARROWHEAD PHARMACEUTICALS, INC.: total equity including noncontrolling interests
• ARROWHEAD PHARMACEUTICALS, INC.: operating lease right-of-use asset
• ARROWHEAD PHARMACEUTICALS, INC.: operating lease liability
• ARROWHEAD PHARMACEUTICALS, INC.: gross property, plant and equipment
• ARROWHEAD PHARMACEUTICALS, INC.: accumulated depreciation on property, plant and equipment
• ARROWHEAD PHARMACEUTICALS, INC.: net intangible assets excluding goodwill
• ARROWHEAD PHARMACEUTICALS, INC.: other noncurrent assets
• ARROWHEAD PHARMACEUTICALS, INC.: other noncurrent liabilities
• ARROWHEAD PHARMACEUTICALS, INC.: accrued current liabilities
• ARROWHEAD PHARMACEUTICALS, INC.: prepaid expenses and other current assets
• ARROWHEAD PHARMACEUTICALS, INC.: current contract liabilities
• ARROWHEAD PHARMACEUTICALS, INC.: pre-tax income or loss from continuing operations
• ARROWHEAD PHARMACEUTICALS, INC.: profit or loss including noncontrolling interests
• ARROWHEAD PHARMACEUTICALS, INC.: comprehensive income or loss
• ARROWHEAD PHARMACEUTICALS, INC.: general and administrative expense
• ARROWHEAD PHARMACEUTICALS, INC.: depreciation expense
• ARROWHEAD PHARMACEUTICALS, INC.: depreciation, depletion and amortization
• ARROWHEAD PHARMACEUTICALS, INC.: amortization of intangible assets
• ARROWHEAD PHARMACEUTICALS, INC.: nonoperating interest expense
• ARROWHEAD PHARMACEUTICALS, INC.: other nonoperating income or expense
• ARROWHEAD PHARMACEUTICALS, INC.: nonoperating income or expense
• ARROWHEAD PHARMACEUTICALS, INC.: current income tax expense or benefit
• ARROWHEAD PHARMACEUTICALS, INC.: interest paid, net
• ARROWHEAD PHARMACEUTICALS, INC.: income taxes paid, net
• ARROWHEAD PHARMACEUTICALS, INC.: proceeds from issuing common stock
• ARROWHEAD PHARMACEUTICALS, INC.: operating lease payments
• ARROWHEAD PHARMACEUTICALS, INC.: change in accounts receivable
• ARROWHEAD PHARMACEUTICALS, INC.: change in accounts payable

Inspect the source

Entity

ARROWHEAD PHARMACEUTICALS, INC. / CIK 0000879407

Captured

2026-09-20T05:01:27.924Z

SEC response SHA-256

df8855dae0055b71bd49c85d7ebc47f72ea6d71536d6bfd857bed2fe95364863

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000879407.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))